US Senators call for end to e-Rxing delay

12 May 2009

11 US Senators have written to the Attorney General Eric Holder and the newly-confirmed Heath and Human Services Secretary Kathleen Sebelius to  call for the federal administration to end delays in a rule to simplify  the electronic prescribing of medicines.

The problem was originally caused by the requirement of the Drug  Enforcement Administration that certain restricted active ingredients  should be prescribed with a physical paper trail (Marketletters passim).  This meant that physicians would not be able to switch over to a  fully-paperless scrip system and jeopardize the hoped for savings of  scrapping paper prescriptions.

According to one of the letter's authors, Senator Sheldon Whitehouse  (Democrat, Rhode Island), only 18% of the USA's physicians currently use  e-prescribing. In addition to an estimated annual $20.0-billion saving  from fewer adverse events caused by prescribing errors, the Senators  argue that the technology is a "logical gateway" towards a comprehensive  countrywide patient record program, which advocates claim would save  $346.0 billion per year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight